Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
17.81
+0.93 (5.51%)
Nov 4, 2024, 4:00 PM EST - Market closed
Kura Oncology Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
142
Market Cap
1.36B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.26B |
Progyny | 1.13B |
Evotec SE | 844.79M |
Schrödinger | 200.63M |
Establishment Labs Holdings | 151.35M |
KURA News
- 4 days ago - Kura Oncology to Report Third Quarter 2024 Financial Results - GlobeNewsWire
- 6 days ago - Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - Business Wire
- 11 days ago - Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 12 days ago - Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors - GlobeNewsWire
- 5 weeks ago - Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology - GlobeNewsWire
- 6 weeks ago - Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors - GlobeNewsWire
- 3 months ago - Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire